

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1. – 18. (Canceled)

Claim 19. (Canceled)

Claim 20. (Canceled)

Claim 21. (Currently Amended) A conjugate according to claim ~~4420~~ wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a photoactive molecule.

Claim 22. (Previously presented) A conjugate according to claim 21 wherein the photoactive molecule is a photosensitizer.

Claim 23. (Previously presented) A conjugate according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

Claim 24. (Currently Amended) A conjugate according to claim 22 wherein the photosensitizer is a derivative of tin (IV) ~~chlorine~~chlorine e6.

Claim 25. (Currently Amended) A conjugate according to claim ~~4420~~ wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a radionuclide.

Claim 26. (Previously Presented) A conjugate according to claim 25 wherein the radionuclide is a β - emitting radionuclide.

Claim 27. (Canceled)

Claim 28. (Canceled)

Claim 29. (Currently Amended) A method for the treatment of an angiogenesis-related pathology in a patient comprising administering a conjugate according to claim ~~44~~²⁰.

Claim 30. (Previously Presented) A method for the treatment of an angiogenesis-related pathology in a patient comprising administering a conjugate according to claim 22 by injections, followed by irradiating said patient.

Claim 31. (Previously Presented) A method according to claim 30 wherein the angiogenesis-related pathology treated is caused by or associated with ocular angiogenesis.

Claim 32. (Previously Presented) A method for the treatment of an angiogenesis-related pathology comprising administering a radionuclide-containing conjugate according to claim 25 by injection.

Claim 33. (Previously Presented) A method according to claim 32 wherein the radionuclide is astatine-211.

Claim 34. (Canceled)

Claim 35. (Canceled)

Claim 36. (Canceled)

Claim 37. (Previously Presented) A conjugate of claim ~~44~~³⁶ wherein the antibody is radiolabeled.

Claim 38. (Previously Presented) A conjugate of claim 37 wherein the antibody is radioiodinated.

Claim 39. (Canceled)

Claim 40. (Currently Amended) A conjugate of claim ~~4439~~ wherein the antibody is produced recombinantly.

Claim 41. (Currently Amended) A conjugate of claim ~~4436~~ wherein the ED-B domain of fibronectin is a human ED-B domain.

Claim 42. (Canceled)

Claim 43. (Previously Presented) A diagnostic kit comprising a conjugate of claim 37 and one or more reagents for detecting angiogenesis.

Claim 44. (Currently Amended) A conjugate comprising (a) an scFv antibody with specific, high affinity for the ED-B domain of fibronectin ~~which has~~ ~~having VH, VL and linker domains with the~~ amino acid ~~sequences~~ ~~sequences~~ encoded ~~by, respectively, by the VH, VL and linker DNA of the~~ DNA insert of ATCC deposit no. PTA-9529 and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

Claim 45. (Canceled)